Brief introduction of Hefei Lifang Pharmaceutical Group

Hefei Cube Pharmaceutical Group, referred to as Cube Group, was incorporated in February 2004. It is a joint-stock enterprise group integrating drug production, sales, research and development, and planting and extracting medicinal materials. The group is headquartered in Hefei, Anhui Province, National High-tech Industrial Development Zone. Business scope: pharmaceutical and food production, pharmaceutical raw materials and biochemical products production, pharmaceutical wholesale and retail, logistics supply, medicinal materials cultivation and breeding, medical equipment sales and other comprehensive investments. In terms of production and operation varieties, four production enterprises have built seven GMP production lines, including granules, capsules, tablets, ointments, injections, oral liquids and traditional Chinese medicine extraction, and 1 the largest deoxyuridine production line in China, and obtained nearly 100 production approvals, including felodipine sustained-release tablets (Ⅱ) and doxazosin mesylate sustained-release tablets. Focusing on domestic and foreign markets and future strategies, the Group successfully operates internal and external resources of the Group. Anhui Rubik's Cube Pharmaceutical Co., Ltd. distributes more than 20 kinds of drugs produced by domestic and foreign manufacturers in the markets above the provincial level, and distributes more than 6,000 kinds of retail drugs.

Since its establishment, the group company has stepped out of a "market first" development road and quickly formed a marketing model with its own characteristics based on two commercial companies. Engage in new drug agency sales in the mode of "building a team to open the market", engage in new drug sales in this enterprise in the mode of "principal-agent system" and operate generic drugs in the mode of "quick batch supermarket". The sales network is distributed in most provinces and key cities in China, such as Anhui, Jiangsu, Beijing and Shanghai. Management is the foundation of enterprise's survival and development. Since its establishment, the Group has attached great importance to the construction of institutional culture. Both the parent company and its subsidiaries have established systematic administrative management and standardized quality management systems, and strictly implemented them. Employees have a strong sense of identity with the company's business philosophy. In their daily work, they pursue the concept of "honesty and professionalism", serve the company, serve the market and contribute to the society.

During the 11th Five-Year Plan period, the Group put forward its development plan, achieving an annual sales income of 654.38 billion yuan, and building a powerful specialized pharmaceutical enterprise group with "osmotic pump controlled release technology" and "separation technology" as the core technology platforms.